Palivizumab profilaksa RSV infekcije
DOI:
https://doi.org/10.5457/ams.v47iSup%201.413Keywords:
Palivizumab, RSV prophylaxis, preterm infants, BPD/CLD, CHD.Abstract
Introduction: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children.
Material and methods: Observational study, in Tuzla Canton, Bosnia and Herzegovina (B&H), reports of infants at high risk for RSV who received at least 1 dose of palivizumab during the 2008-2016 RSV seasons.
Results: Across 8 RSV seasons, from 2008/9 to 2016/17, 267 infants were enrolled (0.66% of livebirths population). Of all infants,147 (55.0%) were enrolled for prematurity only, 7 (2.6%) for bronchopulmonary dysplasia/ chronic lung disease (BPD/CLD), 115 (43.0% ) for congenital heart disease (CHD), and 5 (1.8%) for other reasons; 129 (46.3%) infants in total were born before 33 weeks. Average gestational age of preterm infants enrolled for prematurity only was 30.1±1.2 weeks; for preterm infants with BPD/CLD it was 30±1.3weeks. Overall average of palivizumab injections was 3.9±1.1. Hospitalization rate related to severe lower respiratory infections (LRI) during the period of protection by palivizumab was 3.3%. Respiratory infections which deserved medical attention were observed in 6.3% infants included in palivizumab prophylaxis.
Conclusion: RSV prophylaxis in Tuzla Canton is provided systematically and successfully, following the national guidance established in 2009. with low hospitalization rate for severe LRI in prophylaxed infants..
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
